Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Nusinersen Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 953,418Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 2SPINRAZA royalties

    02 8Spinraza

    03 2Spinraza Royalties

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Spinraza

    Nusinersen

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Spinraza

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Biogen

    Nusinersen

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2020 Revenue in Millions : 2,052

    2019 Revenue in Millions : 2,097

    Growth (%) : -2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : SPINRAZA royalties

    Nusinersen

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : SPINRAZA royalties

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Ionis Pharmaceuticals

    Nusinersen

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2020 Revenue in Millions : 287

    2019 Revenue in Millions : 293

    Growth (%) : -2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Spinraza

    Nusinersen

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Spinraza

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Biogen

    Nusinersen

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2021 Revenue in Millions : 1,905

    2020 Revenue in Millions : 2,052

    Growth (%) : -7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : SPINRAZA royalties

    Nusinersen

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : SPINRAZA royalties

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Ionis Pharmaceuticals

    Nusinersen

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2021 Revenue in Millions : 268

    2020 Revenue in Millions : 287

    Growth (%) : -7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Spinraza

    Nusinersen

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Spinraza

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Biogen

    Nusinersen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2022 Revenue in Millions : 1,794

    2021 Revenue in Millions : 1,905

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Spinraza Royalties

    Nusinersen

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Spinraza Royalties

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Ionis Pharmaceuticals

    Nusinersen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2022 Revenue in Millions : 242

    2021 Revenue in Millions : 268

    Growth (%) : -10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Spinraza

    Nusinersen

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Spinraza

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Biogen

    Nusinersen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2023 Revenue in Millions : 1,741

    2022 Revenue in Millions : 1,794

    Growth (%) : -3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Spinraza Royalties

    Nusinersen

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Spinraza Royalties

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Ionis Pharmaceuticals

    Nusinersen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2023 Revenue in Millions : 240

    2022 Revenue in Millions : 242

    Growth (%) : -1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Spinraza

    Nusinersen

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Spinraza

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Biogen

    Nusinersen

    Main Therapeutic Indication : Spinal Muscular Atrophy

    Currency : USD

    2018 Revenue in Millions : 1,724

    2017 Revenue in Millions : 884

    Growth (%) : 95%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Spinraza

    Nusinersen

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Spinraza

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Biogen

    Nusinersen

    Main Therapeutic Indication : Spinal Muscular Atrophy

    Currency : USD

    2017 Revenue in Millions : 884

    2016 Revenue in Millions : 5

    Growth (%) : 19,111

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF